Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at Upcoming August Investor Conferences

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies...
July 23, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at...
July 10, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibitionOV329...
July 01, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target...
June 17, 2024 06:55 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat

Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key...
May 14, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1,...
May 13, 2024 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
April 04, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies...
March 08, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or...
February 28, 2024 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...